News

XTANDI is the first and only androgen receptor pathway inhibitor (ARPI) indicated and reimbursed in Ontario for use in patients with nmCSPC with biochemical recurrence at high risk for metastasis MARKHAM, ON, June 26, 2025 – Today, Astellas Pharma Canada, Inc. announced that XTANDI® (enzalutamide) is now funded by the Ontario Drug Benefit Program under the Exceptional Access Program for the...

VEOZAH® (fezolinetant film-coated tablets) Now Available in Canada, First and Only Non-hormonal NK3 Antagonist Indicated for Vasomotor Symptoms (VMS) Associated with Menopause New treatment option now available for women experiencing hot flashes and night sweats associated with menopause MARKHAM, ON, March 18, 2025 – Today, Astellas Pharma Canada, Inc. is pleased to announce that VEOZAH®...

Astellas Receives Health Canada Approval for VYLOY ® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer VYLOY is the first and only therapy approved in Canada to target claudin 18.2, a biomarker positively expressed by 38% of patients with advanced gastric cancer 1 , 2 Treatment with VYLOY shown to significantly extend both progression-free...

New treatment option helps fill unmet need for women experiencing hot flashes and night sweats associated with menopause MARKHAM, ON, December 3, 2024 – Today, Astellas Pharma Canada, Inc. is proud to announce the Health Canada approval of VEOZAH ® (fezolinetant film-coated tablets), the first and only non-hormonal treatment indicated for the treatment of moderate to severe vasomotor symptoms (VMS...

HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy Canadian team has dosed first patient in HIGHLIGHT 1™ Phase 3 study Markham, ON, August 27, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), the parent company of...